Posts

End-to-end vector manufacturing optimizes batch success and delivers more doses at lower cost.

The Institute for Clinical and Economic Review (ICER) concluded Tuesday that gene therapies for hemophilia A and B are worth it even at a hefty lifetime cost of $2.5 million.